Notes on research infrastructure, clinical trial operations, and health-system innovation from Sikara Consultancy.
A summary and policy analysis of the first peer-reviewed demonstration of generative AI designing complete, functional bacteriophage genomes - what the science shows, why it matters for antimicrobial resistance, and the biosecurity governance gap it exposes. Sikara’s belief is that the question is not “can it be done” rather the question to ask is “should it be done”.
In a July 15, 2026 letter, the Agency for Healthcare Research and Quality (AHRQ), broadly notified researchers it was halting at least 104 active grants, many aimed at improving patient safety [1]. Congress appropriated $345 million for AHRQ in fiscal 2026, but the agency had spent less than $15 million on grants and had not issued a single new award in over a year at the time of the letter [1]. This follows a near-total staffing collapse: roughly 75% of AHRQ's workforce is reduced since early 2025, leaving 74 employees where there were once close to 300 [1]. For sponsors, health systems, and sites that rely on AHRQ-funded safety and quality infrastructure, this is a live funding and operational risk, and litigation and congressional pushback are already underway.
Clinical research in 2026 sits at the intersection of three forces: artificial intelligence maturing from pilot to production, regulatory modernization finally taking effect after years of drafting, and mounting financial pressure on the sites that execute trials. In addition to these three, decentralization of clinical trials and personalized medicine is taking traction. The global clinical trials market is on track to expand from $127.16 billion in 2025 to $135.51 billion in 2026, and to reach $176.32 billion by 2030; growth increasingly driven by AI adoption and decentralized trial models rather than simple volume increase. At the same time, more than 70% of research sites report active financial stress, and federal funding volatility has already disrupted hundreds of active studies. The sponsors and sites that adapt fastest to this combination of technological opportunity and operational strain will define the next five years of the industry.
Clinical trials remain the backbone of medical innovation, yet the industry continues to face a persistent and costly paradox: despite unprecedented scientific advancement, most trials struggle to enroll and retain participants. At Sikara, we believe the industry must shift from reactive enrollment tactics to proactive, system level readiness. This requires rethinking feasibility, redesigning workflows, and elevating research as a strategic asset within health systems.
The clinical trial industry is experiencing an unprecedented wave of digital transformation. Sponsors and contract research organizations (CROs) are deploying a growing roster of technologies such as electronic data capture, remote monitoring, AI tools, eConsent, eRegulatory systems, and patient-facing apps all with the genuine intention of accelerating trials, improving data quality, and reducing burden on everyone involved. Yet the sites executing trials frequently describe the opposite experience. Rather than feeling empowered by innovation, sites report drowning in platforms, logins, and training requirements. Tools meant to save time often consume it. Trust in sponsor partnerships erodes when technology feels imposed rather than collaborative. This white paper argues that the problem is not the technology itself but the way it is deployed. Drawing on frontline site perspectives and operational best practices, it outlines a framework built on four principles: co-designing with sites, streamlining rather than stacking systems, minimizing the training footprint, and demonstrating transparent value. The central thesis is straightforward: every new technology must reduce clicks, queries, or redundancies and training must be proportional to the benefit it delivers.
Introducing our new home for perspectives on research infrastructure, clinical trial operations, and health-system innovation.